Publication date: Aug 07, 2024
The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This paper summarizes the clinical outcomes of 18 severe haemophilia A (SHA) patients who completed one year on the CHIPS and 3 more years of follow-up. Clinical follow-up was based on the CHIPS protocol (from July 2018 to July 2021). Escalation was based on index joint bleeding, and serial ultrasound (greyscale and colour Doppler) examinations of the index joints (both sides of the ankles, knees and elbows) were conducted every 6 months via a scoring system. A total of 18 SHA patients completed the 3-year study. Fifteen patients dropped out due to the financial crisis during the COVID-19 pandemic in China. The median age was 5. 4 (range 4. 3-6. 9) years. A significant reduction in haemarthrosis was achieved, with mean annual bleeding rates reduced from 18. 9 +/- 2. 8 to 1. 7 +/- 0. 4 (p
Concepts | Keywords |
---|---|
Boys | Bleeding |
China | China |
July | Haemarthrosis |
Pandemic | Haemophilia A |
Individualized prophylaxis |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | haemophilia |
disease | VO | dose |
disease | VO | protocol |
disease | MESH | bleeding |
disease | MESH | COVID-19 pandemic |